Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

- PMLiVE

Shire adds Sara Mathew to board of directors

Comes as firm aims to become global biotechnology leader

- PMLiVE

Boehringer Ingelheim appoints Andreas Neumann as HR lead

He will also join the company's board ofmanaging directors

- PMLiVE

Bringing about digital health change

Qualcomm's Rick Valencia on what the future could hold

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

- PMLiVE

mRNA – message received

Assessing the growing pharma interest in modified messenger RNA

- PMLiVE

EM Imaging appoints new chairman

John Jeans to bring firm to forefront of molecular imaging market

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

- PMLiVE

First-ever World Hepatitis Summit calls for national programmes

Follows rise in hepatitis deaths for fifth consecutive year

- PMLiVE

NICE turns down Celgene’s Otezla once again

Concludes the drug's cost outweighs its benefit for psoriatic arthritis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links